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Abstract
Background: A considerable portion of the HIV pandemic is composed of people under antiretroviral therapy,
many of whom get a late diagnosis. Patients starting antiretroviral therapy (ART) at a very advanced stage of HIV
disease attain a low recovery of CD4 T cells. Factors associated with poor recovery are incompletely described. This
study aimed at finding variables associated with CD4 T cell recovery in late-presenting HIV patients.
Methods: We studied a cohort of HIV+ patients initiating ART with very low basal CD4 T cell counts. We defined
immune recovery as the net increase in circulating CD4 T cell counts after one year on ART. We analyzed diverse
routine laboratory determinations at different times using Least Absolute Shrinkage and Selection Operator (LASSO),
adaptive LASSO and Conditional Inference Random Forest.
Results: CD4/CD8 ratio, % CD4 T cells and CD8 T cell counts at different times were the main recovery correlates,
validated by all approaches. Unexpectedly, basal hematocrit was a consistent predictor. Additionally, week 24
creatinine had a high lasso coefficient, and alkaline phosphatase had a high conditional inference random forest
coefficients, although neither was verified by other tests.
Conclusions: CD4 T cell proportions are associated with CD4 T cell recovery, independently of cell counts.
Inflammation-related variables could also affect reconstitution. These accessible variables may reflect underlying
mechanisms and could improve the follow up of patients starting ART with an advanced HIV infection.
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Introduction
Currently, about 21 million HIV+ patients are accessing
antiretroviral therapy (ART) [1] and face important
health challenges. Even if they reach an undetectable
blood viral load (VL) with ART, some of them attain a
poor recovery of CD4 T cells in blood [2, 3]. These pa-
tients remain mostly free of opportunistic infections, but
they have an increased incidence of non-AIDS defining
illnesses [4]. CD4 T cell count at ART initiation is today
the most usual predictor of the magnitude of recovery of
CD4 T cells under ART [5, 6]. It is thus likely that a per-
son with HIV initiating ARV at a late phase of infection
will recover CD4 T cells deficiently. This is aggravated
by the high rate of late diagnosis in different countries
and regions [7–10].
With the aim of finding variables, other than basal
CD4 T cells count, associated with immune reconstitu-
tion, we analyzed data from a cohort of 67 patients that
initiated antiretroviral therapy with very low CD4 T cell
counts, using the machine learning models Least Abso-
lute Shrinkage and Selection Operator (LASSO), adap-
tive LASSO and Conditional Inference Random Forest.
The latter, less biased by correlations among independ-
ent variables.
Patients and methods
We utilized data from a previous study cohort [11, 12]
of patients starting antiretroviral therapy (ART) and
were followed up one year. The study was approved by
our Institutional Research and Ethics Board (code C04–
08), and all patients signed informed consent complying
with the Helsinki Declaration.
CD4 T cell and CD8 Tcell counts (TriTest kit, FACS-
Calibur system, Becton Dickinson, San Jose, CA, USA),
and plasma VL (Cobas Amplicor-PCR-Monitor HIV-1
system, Roche Diagnostics, Indianapolis, IN, USA) were
measured at the Center for Research in Infectious Dis-
eases of our Institute. We included blood biometry,
blood chemistry, and liver function tests, performed at
the Clinical Laboratory of our Institute [11].
We used Least Absolute Shrinkage and Selection Op-
erator (LASSO) as implemented in the R package
“glmnet” with default parameters [13, 14] to find the
main linear independent predictors of CD4 T cell recov-
ery, which was defined as the net increment of CD4 T
cells/mm3 blood (delta CD4 T cells) in the first year of
treatment (week 52 CD4 T cell counts minus basal
counts). This measure was chosen because a great por-
tion of patients did not achieve counts above 200 or 350
CD4 T cells/mm3 blood) at week 52, which are thresh-
olds used to define satisfactory reconstitution.
LASSO achieves model fitting and feature selection
simultaneously [15]. It was implemented using a Leave
One Out Cross validation (LOOC), based on training
the machine learning algorithm with N-1 samples (N =
total of samples), and evaluating the adjustment with a
sample not yet known by the model. The implementa-
tion of "glmnet" standardizes data by default and rescales
the coefficients to be returned. Scaling is required only
by this model.
LASSO analysis allows no missing values, so raw data
from 99 patients (Supplementary File 1_Raw Data) were
processed in order to obtain a data set with the maximal
number of linear variables having no missing values.
Data processing yielded 67 patients with 53 linear variables
used as independent variables in the model (Supplementary
File 2_Clean Data, and Supplementary File 3_Variable iden-
tification). All chosen patients had reached undetectable VL
at week 52, and had available CD4 T cell counts at
weeks 0 (basal), 8, 12, 24, 39, and 52 after treatment
initiation. We included two patients with detectable
low viral loads at week 52, because they corresponded
to viral blips, according to accepted definitions [16].
Both had reached undetectable viral loads on week 39,
just before week 52, and had subsequent undetectable
viral loads after 104 weeks on treatment.
The 53 variables comprised mainly standard routine
laboratory tests, in addition to HIV treatment follow-up
variables determined at fixed time points (weeks 0, 8, 24,
39, and 52 weeks). Basal age and body-mass index were
also included. We excluded week 52 and basal CD4 T
cell count because delta CD4 T cell (our dependent vari-
able) is arithmetically obtained with them. Therefore,
our study yields predictors additional to nadir CD4 T
cells.
A linear regression was done using the 20 variables
with the greatest LASSO coefficients (top 20 contribut-
ing to the model), as in previous studies [17, 18], with
the purpose of assessing statistical significance, thus pro-
viding a simple output that is easy to interpret. The lin-
ear model used all samples at once (N = 67), while
LASSO performed N iterations using N-1 different
Table 1 Basal values for different variables of the studied
cohort. IQR, inter-quartile range
Variable Median IQR
Age (years) 35 29.9–41.3
Body-mass index 22 20.4–23.8
CD4 T cell count (cells/mm3 blood) 48 21–105
%CD4 T cells 5 2.6–7
CD8 T cell count (cells/mm3 blood) 847 532–1256
%CD8 T cells 69 60–76
CD4/CD8 ratio 0.068 0.03–0.12
VL (HIV RNA copies/mL blood) 328,000 108,000–744,000
Log VL 5.52 5.03–5.87
CD4 T cell count increment in one year 196 137–246
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Fig. 1 Cohort’s response to antiretroviral treatment over one year. a, Viral load (HIV RNA copies/mL blood). b, CD4 T cell count (cells/mm3 blood)
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variable sets (N-1 = 66). This provided additional valid-
ation to LASSO results.
To evaluate possible over-fitting, the linear regression
used leave-one-out cross validation (given the small sim-
ple size). As with LASSO, we performed N linear regres-
sions, training with n-1 samples, plotting the predictions
for the sample that was unknown to the model.
LASSO tends to group correlated variables, and ran-
domly selects one of them and shrinks the others to
zero, which may lead to over-fitting. To address this
limitation, we generated a model using partial correla-
tions with adaptive LASSO using “adalasso.net”, which
mitigates overfitting. We also generated a Conditional
Inference Random Forest with “cforest” function of the R
Package “Party”, which is suitable for models involving
multicollinearity. It can measure variable importance in
combination (with “varimp” function), and it avoids
overfitting. While LASSO assumes a linear relation, con-
ditional inference random forest can model non-linear
relationships between variables. Data analyses were per-
formed using R 3.6.1 [14]. The scripts can be found at
https://github.com/caramirezal/vihCohort/blob/master/
scripts/article_figures.R
Additionally, we performed univariate regressions of
week 24 CD4/CD8 ratio with percentages of subpopula-
tions of CD4 and CD8 T cells. This analysis was done
using SPSS software.
Results
Basal features of patients are displayed in Table 1.
All patients reached undetectable VL at week 52 after
initiating treatment (Fig. 1 A). Sixty-four patients were
male and 3 female. Patients’ basal CD4 T cell counts
ranged from 3 to 275 CD4 T cells/mm3 blood (Table 1).
Only 17 patients had basal counts above 100, and only 4
above 200 (Fig. 1 B).
The 20 variables with the highest LASSO coefficient
included CD4/CD8 ratio at weeks 52, 39, 8, 12, and 24
Fig. 2 LASSO-selected variables with the highest coefficients (top 20). Plotted values correspond to transformed coefficients. For each variable,
the transformed value equals the natural logarithm of the absolute value plus 1. Green, coefficients with positive value. Salmon, coefficients with
a negative value. W, week under treatment; Cr, serum creatinine; %CD4, % CD4 T cells; HCT, hematocrit; FB glu, fasting blood glucose; VL, viral
load (HIV mRNA copies/mL blood); AST, Aspartate transaminase
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(Fig. 2), followed by week 24 serum creatinine, and week
8 CD4/CD8 ratio. Next, basal %CD4 T cells (− 11.09),
week 52 %CD4 T cells, week 52 %CD8 T cells and basal
hematocrit. All variables are shown in Supplementary
File 4.
A linear model using the 20 LASSO-selected variables
with the greatest coefficients (Fig. 3A, Supplementary
File 5) showed a fitting of R2 = 0.72, F = 170.4, DF = 65,
p < 2.2X10− 16, while a linear model using basal CD4 T
cell counts as the single independent variable did not
predict the delta CD4 T cells (adjusted R2 = 0.034, F =
3.33, DF = 65, p = 0.073, Fig. 3 B).
Twelve of the major LASSO–selected variables were
also selected by adaptive lasso. They comprised week 52
and 39 CD4/CD8 ratio, week 24 creatinine, week 8
CD4/CD8 ratio, basal %CD4 T cells, week 52% CD4 T
cells, week 52% CD8 T cells, basal hematocrit, week 24
CD/CD8 ratio, basal leucocyte count, week 52 viral load
and week 52 CD8 T cell counts. The coefficients of all
variables are listed in Supplementary File 6.
Conditional inference random forest analysis yielded
26 variables with positive importance coefficients (Fig. 4).
Among them, eight corresponded to major variables se-
lected by both LASSO and adaptive LASSO: CD4/CD8
ratio at weeks 24, 39 and 52, % CD4 T cells at weeks 0
and 52, week 52 CD8 T cell count and percentage, as
well as basal hematocrit. These eight variables are thus
independently validated. Conditional inference random
forest also assigned a positive coefficient to the occur-
rence of immune reconstitution inflammatory syndrome
(IRIS) (importance coefficient = 81.06), which had been
selected by adaptive LASSO (coefficient = − 13.3). Add-
itionally, it assigned a positive coefficient of 345.26 to
week 24 alkaline phosphatase, which was not selected by
LASSO or adaptive LASSO analysis. (See the complete
results in Supplementary File 7).
Fig. 3 Comparison of linear models using A, Top 20 LASSO variables, and B, basal CD4 T cell counts, as predictors of net increment in CD4 T cell
counts after 52 weeks on ART (“delta T CD4”). For A, regression was performed using leave-one-out cross validation, performing N linear
regressions, training with N-1 samples, plotting the predictions for the sample that was unknown to the model. Adjusted R2 = 0.71960667, F =
170.383628 (DF = 65) p = 7.915957X10− 20. B, linear model with basal (week 0) CD4 T cell counts. Adjusted R2 = 0.034, F = 3.33 (DF = 65), p = 0.07
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CD4/CD8 ratio values remained below 1 (known as an
inverted coefficient [19]), even though they increased
consistently during the whole follow up (Fig. 5).
In univariate correlations, week 24 CD4/CD8 ratio cor-
related negatively with the basal (week 0) percentage of
CD28− cells among effector memory CD4 T cells, basal
blood CD8 T cell count, week 24 percentage of activated
naive CD8 T cells, and week 24 percentage of CD28−
naive CD4 T cells (Table 2). Week 24 CD4/CD8 ratio
positively correlated with week 24 percentage of memory
CD8 T cells (Table 2).
Discussion
In many studies reconstitution is indicated by an end
point count of CD4 T cells after initiation of antiretroviral
treatment (ART) [20–22]. Other studies classify patients
as good or poor responders according to a fixed arbitrary
increase in CD4 T cell counts [23]. It is well described that
initial counts predict end point ones [5, 6]. In contrast to
end-point counts, our work studies the net increment in
CD4 T cell counts (delta CD4 T cells), which also deter-
mines reconstitution. In the current late-presenting co-
hort, we found that initial CD4 T cell counts did not
Fig. 4 Mean importance coefficients obtained by conditional inference random forest analysis. Variables with positive coefficients (contributing to
the prediction of delta CD4) are plotted
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predict the net gain of CD4 T cells. By using a set of
LASSO-selected variables, we built a model with a signifi-
cant fit to this reconstitution variable. These variables are
important because they may reflect mechanisms under-
lying CD4 T cell recovery. Among them, those at ART ini-
tiation or early thereafter may be further evaluated as
potential predictors of CD4 T cell gain.
Our findings extend the broad context of CD4/CD8
ratio studies. In very elderly people (> 80 years) without
HIV, an inverted CD4/CD8 ratio (lower than 1) was
associated with increased mortality [24], increased acti-
vation of CD8 T cells, a shrunken T cell repertoire [25],
low CD4 T cell percentages, decreased T cell response
to mitogens, and a greater frequency of cytomegalovirus
and Epstein Barr infections [24, 26]. In the setting of un-
treated HIV infection, CD4/CD8 inversion was a pre-
dictor of untreated HIV infection progression [19]. In
HIV+ patients starting ART, CD4/CD8 was a predictor
of AIDS clinical events and death [27]. It would be ex-
pectable to find a higher overall morbidity in the present
cohort, which started antiretroviral treatment with a
great loss of CD4 T cells [28].
CD4/CD8 ratio is associated with non-AIDS events in
people with controlled viremia under ART [29, 30]. In
these patients, CD4/CD8 is also correlated with activation
and senescence of T cells [29, 31]. In our cohort, week 24
CD4/CD8 ratio (the earliest predictive variable validated
by the three methods) correlated negatively with the
Fig. 5 CD4/CD8 ratio throughout the first year under ART. Results are presented as Log10. Each dot corresponds to a patient’s value (with
possible overlapping). A smooth curve was fitted to show trends
Table 2 Phenotypes of CD4 and CD8 T cells significantly
correlating with week 24 CD4/CD8 ratio. Only basal and week
24 values were analyzed. Rho values correspond to univariate
Spearman correlation. N, sample size, according to availability of
data
Rho p N
Basal %CD28− of effector memory CD4 T cells -,540 0.02528871 17
Week 24%CD38+ HLADR+ of naive CD8 T cells -,397 0.04963967 25
Week 24%memory of total CD8 T cells ,408 0.04281341 25
Week 24%CD28− of naive CD4 T cells -,428 0.04679031 22
Basal naive CD8 T cells/mm3 blood -,487 0.0183949 23
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contemporaneous percent of activated naive CD8 T cells
and the frequency of differentiated (CD28−) naive CD4 T
cells. It also correlated negatively with the basal percent-
ages of CD28− (senescent) effector memory CD4 T cells.
This positive correlation with frequencies of less differen-
tiated subpopulations, and a negative correlation with T
cell activation, concur with previous findings [29, 32].
Our findings extend the predictive capacity of CD4/
CD8 ratio to net CD4 T cell recovery under ART. There
are two previous studies addressing this variable. A study
of 30 patients with relatively preserved CD4 T cell
counts found a correlation of CD4/CD8 ratio with CD4
T cell increment two years after ART initiation [33].
Another study did not find any association six months
after ART initiation [34]. In our study of patients start-
ing ART with profound CD4 T cell loss, CD4/CD8 ra-
tio at weeks 24, 39 and 52 were associated with
absolute CD4 T cell gain, according to three machine
learning methods.
It is noteworthy that in our advanced-stage cohort, pro-
portions of CD4 T cells were major correlates of CD4 T cell
gain. Percent CD8 T cells and % CD4 T cells, as well as
basal %CD4 T cells were consistently associated with CD4
T cell recovery by all models. Moreover, week 52 CD8 T cell
counts, which determine CD4/CD8 ratio, were among these
variables. In this regard, CD8 T cells are expanded in HIV
disease [35–37]. These findings suggest a possible independ-
ence of CD4 T cell proportions as correlates of immune re-
covery. In line with this possible independence, CD4/CD8
ratio correlated with CD4 T cell increment after two years
on ART, even though basal CD4 T cell counts did not cor-
relate with CD4 T cell increment [33]. Interestingly, the pa-
tients in this study had basal CD4 T cell counts significantly
higher than our cohort (median 380, IQR 310–500, Mann
Whitney U= 81, p < 0.001), suggesting a broad predictive
capacity of CD4/CD8 ratio. Our findings extend the disad-
vantage of a low CD4/CD8 ratio, which is already known to
predict the incidence of non-AIDS-defining illnesses, even
when CD4 T cells counts are normal [38], and even when
the analysis is adjusted for CD4 T cell counts [29].
Basal hematocrit was selected by the two LASSO models,
with a negative coefficient, and had a positive importance
coefficient in conditional inference random forest analysis.
Values ranged between 27.3 to 53.8, mostly within our In-
stitute reference values (37–54), and there were no signs of
anemia in the cohort. Whether hematocrit is reflecting a
mechanism altering CD4 T cell recovery requires further
research. This routine laboratory determination might help
detecting patients with a higher risk of poor reconstitution.
The occurrence of immune reconstitution inflammatory
syndrome (IRIS) was selected by adaptive LASSO and by
conditional inference random forest (81.1). Also indicating
inflammation, week 24 alkaline phosphatase was selected
by conditional inference random forest, but was not
selected by LASSO models. In univariate regression, it cor-
related negatively with delta CD4 T cells (Spearman’s Rho =
− 0.25, p = 0.04). A deleterious effect of inflammation on
immune reconstitution under ART has been described [39,
40], and could be related with CD4/CD8 ratio [31].
A limitation of our study is the lack of additional mea-
sures of model performance, like OOB error for Condi-
tional Inference Random Forest. Nevertheless, the
consistency between different algorithms supports the im-
portance of our variables.
Conclusion
Among patients initiating ART in a very advanced stage
of HIV infection, proportions of CD4 T cells are associ-
ated with the immunological response to antiretroviral
therapy, possibly reflecting reconstitution determinants
other than initial CD4 T cell counts. Together with IRIS
and alkaline phosphatase, they comprise a set of access-
ible variables that could be used to predict the response
to antiretroviral therapy.
Supplementary information










ALP: Alkaline phosphatase; AST: Aspartate transaminase; ART: antiretroviral
therapy; Cr: Creatinine; FB glu: Fasting basal glucose; HCT: Hematocrit;
IRIS: Immune reconstitution inflammatory syndrome; LASSO: Least Absolute
Shrinkage and Selection Operator; VL: Viral load; W: Week; TGL: Triglycerides;
TCM: Central memory CD4 T cells
Acknowledgements
D.P. R-R and C.R contributed equally to this work.
Authors’ contributions
DPR-R performed cohort follow up and sample collection, organized patient
visits, medical staff collection of data, prepared samples, did the flow
cytometry analysis of patient’s cells and analyzed some of the plasma
variables. CR performed data analysis. II-R analyzed data, CEO analyzed data,
AP-P was the attending physician and collected the clinical data, GO-G, FC,
JRR, and DW-M performed laboratory determinations, WJ designed the study,
interpreted results and wrote the manuscript, GRT conceived and designed
the study, followed up patients, EE conceived and designed the study, inter-
preted results, analyzed data, and wrote the manuscript. The author(s) read
and approved the final manuscript.
Funding
This work was financed by grant NIAID AI-1288864, U. S. A. (W.J.), grant 24011 (P-
50478) from the Mexican National Research and Technology Council (CONACyT)
(E. E.), and grants from the Mexican Government (Comisión de Equidad y Género
de las Legislaturas LX-LXI y Comisión de Igualdad de Género de la Legislatura LXII
de la H. Cámara de Diputados de la República Mexicana) (G. R-T.).
Romero-Rodríguez et al. Translational Medicine Communications             (2020) 5:6 Page 8 of 10
Availability of data and materials
The code and datasets generated and analysed during the current study are
available in the github repository.
https://github.com/caramirezal/vihCohort/blob/master/scripts/article_figures.R
Ethics approval and consent to participate
The study was approved by our Institutional Research and Ethics Board
(registration number C04–08), and all patients signed informed consent in




The authors declare that they have no competing interests.
Author details
1Cell Cytometry Core Facility, Instituto Nacional de Enfermedades
Respiratorias Ismael Cosío Villegas, Mexico City, Mexico. 2Department of
Molecular Biology and Biotechnology, Instituto de Investigaciones
Biomédicas, Universidad Nacional Autónoma de México, Mexico City, Mexico.
3Wellcome -MRC Cambridge Stem Cell Institute and Department of
Haematology, University of Cambridge, Cambridge, UK. 4Center for Infectious
Diseases Research (CIENI), Instituto Nacional de Enfermedades Respiratorias
Ismael Cosío Villegas, Mexico City, Mexico. 5Laboratory of Integrative
Immunology, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío
Villegas, Calzada de Tlalpan 4502, 14080 Mexico City, Mexico. 6Department of
Microbiology and Immunology, Division of Infectious Diseases, Department
of Medicine, Medical University of South Carolina, Charleston, SC, USA.
Received: 1 October 2019 Accepted: 24 March 2020
References
1. UNAIDS. Fact Sheet-World AIDS Day 2017 [Internet]. UNAIDS. 2017 [cited
2018 Feb 5]. Available from: http://www.unaids.org.
2. Lederman HM, Williams PL, Wu JW, Evans TG, Cohn SE, McCutchan JA, et al.
Incomplete immune reconstitution after initiation of highly active
antiretroviral therapy in human immunodeficiency virus-infected patients
with severe CD4+ cell depletion. J Infect Dis. 2003;188(12):1794–803.
3. Kelly C, Gaskell KM, Richardson M, Klein N, Garner P, MacPherson P.
Discordant immune response with antiretroviral therapy in HIV-1: a
systematic review of clinical outcomes. PLoS One. 2016;11(6):e0156099.
4. Zoufaly A, Cozzi-Lepri A, Reekie J, Kirk O, Lundgren J, Reiss P, et al. Immuno-
virological discordance and the risk of non-AIDS and AIDS events in a large
observational cohort of HIV-patients in Europe. PLoS One. 2014;9(1):e87160.
5. Mutoh Y, Nishijima T, Inaba Y, Tanaka N, Kikuchi Y, Gatanaga H, et al.
Incomplete recovery of CD4 cell count, CD4 percentage, and CD4/CD8 ratio
in patients with human immunodeficiency virus infection and suppressed
Viremia during long-term antiretroviral therapy. Clin Infect Dis Off Publ
Infect Dis Soc Am. 2018;67(6):927–33.
6. Gras L, May M, Ryder LP, Trickey A, Helleberg M, Obel N, et al. Determinants
of Restoration of CD4 and CD8 Cell Counts and Their Ratio in HIV-1-Positive
Individuals With Sustained Virological Suppression on Antiretroviral Therapy.
J Acquir Immune Defic Syndr 1999. 2019;80(3):292–300.
7. Martin-Onraët A, Volkow-Fernández P, Alvarez-Wyssmann V, González-
Rodríguez A, Casillas-Rodríguez J, Rivera-Abarca L, et al. Late diagnosis due
to missed opportunities and inadequate screening strategies in HIV infected
Mexican women. AIDS Behav. 2017;21(2):505–14.
8. Rampaul M, Edun B, Gaskin M, Albrecht H, Weissman S. Cost-effectiveness
analysis of early vs late diagnosis of HIV-infected patients in South Carolina.
South Med J. 2018;111(6):355–8.
9. Wilton J, Light L, Gardner S, Rachlis B, Conway T, Cooper C, et al. Late
diagnosis, delayed presentation and late presentation among persons
enrolled in a clinical HIV cohort in Ontario, Canada (1999-2013). HIV Med.
2019;20(2):110–20.
10. Gargallo-Bernad C, Sangrós-González FJ, Arazo-Garcés P, Martínez-Álvarez R,
Malo-Aznar C, Gargallo-Bernad A, et al. Missed opportunities in the
diagnosis of human immunodeficiency virus infection in the region of
Aragon. Late diagnosis importance. Enferm Infecc Microbiol Clin. 2019;37(2):
100–8.
11. Espinosa E, Ormsby CE, Vega-Barrientos RS, Ruiz-Cruz M, Moreno-Coutino G,
Pena-Jimenez A, et al. Risk factors for immune reconstitution inflammatory
syndrome under combination antiretroviral therapy can be aetiology-
specific. Int J STD AIDS. 2010;21(8):573–9.
12. Espinosa E, Romero-Rodríguez DP, Cantoral-Díaz M-T, Reyes-Terán G.
Transient expansion of activated CD8+ T cells characterizes tuberculosis-
associated immune reconstitution inflammatory syndrome in patients with
HIV: a case control study. J Inflamm Lond Engl. 2013;10(1):21.
13. Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear
models via coordinate descent. J Stat Softw. 2010;33(1):1–22.
14. Core R. Team. R: a language and environment for statistical computing
[internet]. Viena: R Foundation for statistical. Computing. 2013; Available
from: http://www.R-project.org/.
15. Tibshirani R. Regression shrinkage and selection via the lasso. J R Stat Soc
Ser B Methodol. 1996;58(1):267–88.
16. Sörstedt E, Nilsson S, Blaxhult A, Gisslén M, Flamholc L, Sönnerborg A, et al.
Viral blips during suppressive antiretroviral treatment are associated with
high baseline HIV-1 RNA levels. BMC Infect Dis. 2016;21(16):305.
17. Mueller-Using S, Feldt T, Sarfo FS, Eberhardt KA. Factors associated with
performing tuberculosis screening of HIV-positive patients in Ghana: LASSO-
based predictor selection in a large public health data set. BMC Public
Health. 2016;13(16):563.
18. Muenchhoff M, Healy M, Singh R, Roider J, Groll A, Kindra C, et al.
Malnutrition in HIV-infected children is an Indicator of severe disease with
an impaired response to antiretroviral therapy. AIDS Res Hum Retrovir. 2018;
34(1):46–55.
19. Margolick JB, Gange SJ, Detels R, O’Gorman MRG, Rinaldo CR, Lai S. Impact
of inversion of the CD4/CD8 ratio on the natural history of HIV-1 infection.
J Acquir Immune Defic Syndr 1999. 2006;42(5):620–6.
20. Anthony KB, Yoder C, Metcalf JA, DerSimonian R, Orenstein JM, Stevens RA,
et al. Incomplete CD4 T cell recovery in HIV-1 infection after 12 months of
highly active antiretroviral therapy is associated with ongoing increased CD4 T
cell activation and turnover. J Acquir Immune Defic Syndr. 2003;33(2):125–33.
21. Marchetti G, Gori A, Casabianca A, Magnani M, Franzetti F, Clerici M, et al.
Comparative analysis of T-cell turnover and homeostatic parameters in HIV-
infected patients with discordant immune-virological responses to HAART.
AIDS Lond Engl. 2006;20(13):1727–36.
22. Gómez-Mora E, Massanella M, García E, Giles D, Bernadó M, Urrea V, et al.
Elevated humoral response to cytomegalovirus in HIV-infected individuals
with poor CD4+ T-cell immune recovery. PLoS One. 2017;12(9):e0184433.
23. Batista G, Buvé A, Ngom Gueye NF, Manga NM, Diop MN, Ndiaye K, et al.
Initial suboptimal CD4 reconstitution with antiretroviral therapy despite full
viral suppression in a cohort of HIV-infected patients in Senegal. Med Mal
Infect. 2015;45(6):199–206.
24. Wikby A, Maxson P, Olsson J, Johansson B, Ferguson FG. Changes in CD8
and CD4 lymphocyte subsets, T cell proliferation responses and non-survival
in the very old: the Swedish longitudinal OCTO-immune study. Mech
Ageing Dev. 1998;102(2–3):187–98.
25. Hadrup SR, Strindhall J, Køllgaard T, Seremet T, Johansson B, Pawelec G,
et al. Longitudinal studies of clonally expanded CD8 T cells reveal a
repertoire shrinkage predicting mortality and an increased number of
dysfunctional cytomegalovirus-specific T cells in the very elderly. J Immunol
Baltim Md 1950. 2006;176(4):2645–53.
26. Wikby A, Ferguson F, Forsey R, Thompson J, Strindhall J, Löfgren S, et al. An
immune risk phenotype, cognitive impairment, and survival in very late life:
impact of allostatic load in Swedish octogenarian and nonagenarian
humans. J Gerontol A Biol Sci Med Sci. 2005;60(5):556–65.
27. Bonnet F, Thiébaut R, Chêne G, Neau D, Pellegrin J-L, Mercié P, et al.
Determinants of clinical progression in antiretroviral-naive HIV-infected
patients starting highly active antiretroviral therapy. Aquitaine cohort,
France, 1996-2002. HIV Med. 2005;6(3):198–205.
28. Rodríguez Arrondo F, von Wichmann MÁ, Camino X, Goenaga MÁ,
Ibarguren M, Azcune H, et al. A case-control study of non-AIDS-defining
cancers in a prospective cohort of HIV-infected patients. Med Clin (Barc).
2018 23;150(8):291–296.
29. Serrano-Villar S, Sainz T, Lee SA, Hunt PW, Sinclair E, Shacklett BL, et al. HIV-
infected individuals with low CD4/CD8 ratio despite effective antiretroviral
therapy exhibit altered T cell subsets, heightened CD8+ T cell activation,
and increased risk of non-AIDS morbidity and mortality. PLoS Pathog. 2014;
10(5):e1004078.
Romero-Rodríguez et al. Translational Medicine Communications             (2020) 5:6 Page 9 of 10
30. Mussini C, Lorenzini P, Cozzi-Lepri A, Lapadula G, Marchetti G, Nicastri E,
et al. CD4/CD8 ratio normalisation and non-AIDS-related events in
individuals with HIV who achieve viral load suppression with antiretroviral
therapy: an observational cohort study. Lancet HIV. 2015;2(3):e98–106.
31. Sainz T, Serrano-Villar S, Díaz L, González Tomé MI, Gurbindo MD, de José
MI, et al. The CD4/CD8 ratio as a marker T-cell activation, senescence and
activation/exhaustion in treated HIV-infected children and young adults.
AIDS Lond Engl. 2013;27(9):1513–6.
32. Serrano-Villar S, Gutiérrez C, Vallejo A, Hernández-Novoa B, Díaz L, Abad
Fernández M, et al. The CD4/CD8 ratio in HIV-infected subjects is
independently associated with T-cell activation despite long-term viral
suppression. J Inf Secur. 2013;66(1):57–66.
33. Buggert M, Frederiksen J, Noyan K, Svärd J, Barqasho B, Sönnerborg A, et al.
Multiparametric bioinformatics distinguish the CD4/CD8 ratio as a suitable
laboratory predictor of combined T cell pathogenesis in HIV infection. J
Immunol Baltim Md 1950. 2014;192(5):2099–108.
34. Castagna A, Galli L, Torti C, D’Arminio Monforte A, Mussini C, Antinori A,
et al. Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-
infected patients during first-line highly active antiretroviral therapy. Antivir
Ther. 2010;15(2):165–75.
35. Nasi A, Chiodi F. Mechanisms regulating expansion of CD8+ T cells during
HIV-1 infection. J Intern Med. 2018;283(3):257–67.
36. Mudd JC, Lederman MM. CD8 T cell persistence in treated HIV infection.
Curr Opin HIV AIDS. 2014;9(5):500–5.
37. Freeman ML, Mudd JC, Shive CL, Younes S-A, Panigrahi S, Sieg SF, et al. CD8
T-cell expansion and inflammation linked to CMV Coinfection in ART-treated
HIV infection. Clin Infect Dis Off Publ Infect Dis Soc Am. 2016;62(3):392–6.
38. Riangwiwat T, Kohorn LB, Chow DC, Souza SA, Ndhlovu LC, Wong JWH,
et al. CD4/CD8 Ratio Predicts Peripheral Fat in HIV-Infected Population. J
Acquir Immune Defic Syndr 1999. 2016;72(1):e17–9.
39. Shive CL, Clagett B, McCausland MR, Mudd JC, Funderburg NT, Freeman ML,
et al. Inflammation Perturbs the IL-7 Axis, Promoting Senescence and
Exhaustion that Broadly Characterize Immune Failure in Treated HIV
Infection. J Acquir Immune Defic Syndr 1999. 2016;71(5):483–92.
40. Lederman MM, Calabrese L, Funderburg NT, Clagett B, Medvik K, Bonilla H,
et al. Immunologic failure despite suppressive antiretroviral therapy is
related to activation and turnover of memory CD4 cells. J Infect Dis. 2011;
204(8):1217–26.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Romero-Rodríguez et al. Translational Medicine Communications             (2020) 5:6 Page 10 of 10
